The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high ...

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have ... 2024, the last full trading day prior to the transaction announcement, and a 21.9% premium to ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

Under the terms of the merger agreement, GHO and Ampersand would acquire all the ... the last full trading day prior to the transaction announcement, and a 21.9% premium to the Company's 20 ...

Under the terms of the agreement, GHO and Ampersand will acquire all outstanding shares held by Avid’s stakeholders for $12.50 a share in cash, which is a 13.8% premium to the Nov. 6, 2024 closing ...

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Craig-Hallum downgraded Avid Bioservices (CDMO) to Hold from Buy with a price target of $12.50, down from $16, after the company said it was getting acquired by GHO Capital and Ampersand Capital. The ...

CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth ... Novo ...